Create New Account Purchaser Login
Search Tenders
Advanced Search
You are not logged in.

Future Procurement Opportunity (FPO) – Supply of Various Vaccines and Influenza Vaccines


Tender Closed
RFx ID : 26018399
Tender Name : Future Procurement Opportunity (FPO) – Supply of Various Vaccines and Influenza Vaccines
Reference # : A1594470
Open Date : Q3 2022
Indicative RFx Release Date  : Q4 2022  [?]
Tender Type : Future Procurement Opportunity (FPO)
Project Status : Awaiting approval  [?]
Indicative Total Value : $25M - $50M  [?]
Tender Coverage : Sole Agency  [?]
Categories :
  • 51000000 - Drugs and Pharmaceutical Products
  • New Zealand
Required Pre-qualifications : None
Contact : Pharmac Procurement Team
Agency Address :
Related Tenders:

Pharmac is planning on issuing a competitive process for supply of Various Vaccines and Influenza Vaccines.

The approximate gross annual expenditure varies by vaccine. Usage data of currently funded vaccines has been provided as an attachment on this FPO listing. Please subscribe to this listing to download.

For current funding restrictions please view the Pharmaceutical Schedule:

Pharmac would also be interested in considering offers for vaccines that use technologies not currently used in vaccines that are funded in New Zealand.

As part of this potential procurement process Pharmac may consider changes to funding eligibility criteria. Please refer to the Pharmac application tracker for consideration of funding for widened access

The suggested approach for suppliers would be to make any funding applications for potential new vaccines or changes to the indications for existing vaccines as soon as possible (but no later than 12 July 2022). For the purposes of the Vaccines RFP process and recognising the long lead times required for vaccine manufacture and supply, the Immunisation Advisory Committee may consider vaccines or indications prior to Medsafe approval in order to support the procurement timelines.

To enable Pharmac to consider listing a vaccine for any currently unfunded indications, we would need a recommendation either from PTAC or from the Immunisation Advisory Committee that the vaccine is suitable for inclusion in the National Immunisation Schedule. The vaccine would then be ranked on the Pharmac’s options for investment list alongside all other funding opportunities.

The next Immunisation Advisory Committee meeting is scheduled for September 2022. Applications for consideration this meeting should be submitted no later than 12 July 2022.

Pharmac is open to changing the way it funds influenza vaccines. We want to enable more equitable health outcomes in a way that is mutually sustainable for both the New Zealand health system and suppliers. We are interested in hearing from suppliers early to help inform the development of this procurement.

RFx Outcome

This tender has been completed.

Further information:
RFP released 11 November, see pharmac website for details

Date RFx was completed/updated: Monday, 14 November 2022 4:04 PM (Pacific/Auckland UTC+13:00)